JPRN-jRCTs031180329已完成1 期
A preliminary open-labeled pharmacokinetic study to examine the effect of cilastatin on the prevention of acute kidney injury in cancer patients undergoing cisplatin-based chemotherapy
Saito Akihiko0 个研究点目标入组 9 人开始时间: 2019年3月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 70age old（—）
- 性别
- All
入选标准
- •Those with Non-small cell lung cancer, stage 4.
- •Those with planning chemotherapy including cisplatin, who have never had chemotherapy so far.
- •Those with PS 0 or 1.
- •Those who have given written informed consent on the use of their clinical data for this trial.
排除标准
- •Those with impaired renal function: eGFR<60mL/min/1.73m2
- •Those who has disease or symptoms thought to be affecting the judgment of efficacy or safety.
- •Those who received antibiotics, antiviral drugs, antifungal drugs within 14 days before incorporation (except for external application, eye drops, or nose drops).
- •Female patients during pregnancy, breast-feeding or pregnancy.
- •Those who judged that the research director is inappropriate as the research subject.
研究者
相似试验
已完成
1 期
A preliminary open-labeled pharmacokinetic study to examine the effect of cilastatin on the prevention of acute kidney injury in cancer patients undergoing cisplatin-based chemotherapyon-small cell lung cancerJPRN-UMIN000030363Department of Applied Molecular Medicine, Kidney Research Center, Niigata University Graduate School of Medical and Dental Science9
进行中（未招募）
不适用
A Phase 1 Open-Label Study of the Pharmacokinetics of Tacrolimus Cream B 0.1% after Twice Daily Topical Administration in Adolescents (= 12 to = 17 Years of Age ) with Psoriasis - Tacrolimus Cream B 0.1% in AdolescentsEUCTR2006-002738-39-LVAstelleas Pharma US, Inc.20
终止
1 期
A Phase 1 study dosing with a Humira® (adalimumab) Enema in Patients with Active Ulcerative Colitis.lcerative colitisOral and Gastrointestinal - Inflammatory bowel diseaseInflammatory and Immune System - Other inflammatory or immune system disordersOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonUlcerative colitisACTRN12620000932965Progenity Inc4
进行中（未招募）
1 期
A clinical trial to find out how much tapentadol is in the blood of children who take tapentadol every 4 hours to treat short-term paiEUCTR2019-000205-77-PLGrünenthal GmbH15
已完成
不适用
An open-label study to assess the pharmacokinetics and safety/tolerability of pulsatile intra-vaginal delivery of a single dose of oxybutynin in healthy femalesNL-OMON51105iGalli BV8